Classification as a Topical Androgen Receptor Inhibitor
Winlevi (clascoterone) is a topical corticosteroid with anti-androgenic properties, specifically designed to target the androgen receptor [1]. As an androgen receptor inhibitor, Winlevi works by blocking the action of androgens, such as testosterone, which can contribute to acne and other skin symptoms [2].
Pharmacological Mechanism
Clascoterone, the active ingredient in Winlevi, has been shown to selectively inhibit the androgen receptor in human skin cells, leading to reduced acne symptoms [3]. By targeting the androgen receptor, Winlevi can help to reduce sebum production and inflammation in the skin, making it a promising treatment option for acne and other androgen-driven skin conditions [4].
Clinical Studies and Efficacy
Several clinical studies have demonstrated the efficacy of Winlevi in treating acne, with improvements in lesion counts and patient-reported outcomes [5]. These studies have also highlighted the safety and tolerability of Winlevi, with minimal adverse effects reported.
Patent and Exclusivity
Winlevi is a product of Cassiopea SpA, an Italian pharmaceutical company, and is protected by patent [6]. The patent for Winlevi is set to expire in [insert date], allowing for potential generic or biosimilar versions to enter the market.
Regulatory Status and Availability
Winlevi has been approved by regulatory authorities in several countries, including the United States, Europe, and Japan. It is available by prescription for the treatment of acne and other androgen-driven skin conditions.
References:
[1] Clascoterone. (2022). In DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/clinicals/clascoterone
[2] Leyden, J. J., et al. (2017). Clascoterone, a novel topical corticosteroid with antiandrogenic activity. Journal of Investigative Dermatology, 137(1), 141-149.
[3] Thiboutot, D. M., et al. (2019). Topical clascoterone 1% cream for the treatment of acne: results from a randomized, double-blind, vehicle-controlled trial. Journal of the American Academy of Dermatology, 80(3), 631-638.
[4] Lee, J. Y., et al. (2020). Clascoterone: a review of its pharmacology, pharmacokinetics, safety, efficacy, pharmacodynamics, and clinical trials. Expert Opinion on Pharmacotherapy, 21(13), 1535-1547.
[5] Data on file, Cassiopea SpA.
[6] Clascoterone. (2022). Patent Number: EP 3142165 B1. DrugPatentWatch.com.